Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131 I-Refractory Differentiated Thyroid Cancer in China
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jan 2022
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 25 Jan 2022 Status changed from active, no longer recruiting to completed.
- 24 Nov 2021 Planned End Date changed from 30 Oct 2021 to 1 Mar 2022.
- 29 Jul 2021 Primary endpoint (Progression-free survival (PFS) has been met according to the results published in the Clinical Cancer Research